Skip to content

Study on the Accessibility and Feasibility of Intelligent Applet for Health Intervention of Cancer Patients

Study on the Accessibility and Feasibility of Intelligent Applet for Health Intervention of Cancer Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05501990
Enrollment
800
Registered
2022-08-16
Start date
2023-07-01
Completion date
2025-12-31
Last updated
2023-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

In the 5G era with the revolutionary improvement of network speed, digital medical care has brought great convenience to health services. There is a lack of mobile medical data on cancer care worldwide. We designed an applet based on mobile intelligent electronic devices with a doctor-patient dual interface for the perioperative management of cancer patients and verified its applicability in the general population. This study aims to specifically improve the applet according to the characteristics of cancer patients, use it to accurately manage and intervene cancer patients, and establish a rapid doctor-patient communication platform, hoping to improve prognosis.

Interventions

BEHAVIORALHealth intervention based on intelligent applet

Patients are jointly managed by a MDT team based on the applet. The supportive intervention based on the applet mainly includes three parts: Nutrition, psychology, and patient management which includes four main parts: Cancer patient education, self-management, patient community, and real-time communication.

Sponsors

Ruijin Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Sign and date informed consent; * Commit to abide by the research procedures and cooperate with the implementation of the whole research process ; * Can adhere to and cooperate with research intervention; * Tumor patients; * Patients/family members can use smart phones to access the Internet; * Patients/family members have sufficient cognitive and reading ability; * No mental illness; * No serious visual impairment

Exclusion criteria

* Equipped with specific devices (such as cardiac pacemaker); * Those who do not meet the conditions listed in the inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
Acceptability of the applet by cancer patients as assessed by questionnaire3 monthsInvestigated by a questionnaire with 33 questions, and compared with other mobile medical methods to explore the accessibility
Acceptability of the applet by medical oncology staff as assessed by questionnaire3 monthsThe questionnaire includes 22 questions, collecting information on attitude feedback, time input, and training cost of medical staff using the mobile medical applet

Secondary

MeasureTime frameDescription
Self-reported quality of life as assessed by ED-5Q-5L scale3 monthsEQ-5D-5L is a set of standardized scales for measuring health status, including 5 dimensions (1-5 points for each dimension) and a VAS for overall assessment of health status. Developed by the European Society for quality of life, it can provide a simple and universal health measurement method for clinical and economic evaluation.
Psychological status as assessed by the HADS scale3 monthsHospital Anxiety and Depression Scale (HADS): A self screening questionnaire composed of 7 anxiety subscales and 7 depression subscales. The total score of each subscale is between 0 and 21. The higher the total score, the more serious the anxiety or depression.
Symptom distress as assessed by the MD Anderson symptom scale3 monthsSymptom distress is assessed with MD Anderson symptom scale, which is composed of 13 symptom severity and 6 symptom interference subscales. It is used to assess the interference of symptoms to patients' daily life. The item scores range from 1 to 10. The higher the average score, the more serious the symptom.

Countries

China

Contacts

Primary ContactLei Huang, PhD, MD
huangleizhenting@126.com0086 021 64370045

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026